Subscribe
flocu
flocu / iStockphoto.com
13 September 2017Americas

Teva sells Paragard contraceptive for $1.1bn

Medical device firm Cooper Companies has agreed to acquire the global rights to Teva’s Paragard intrauterine device (IUD) for $1.1 billion.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Teva and generics in SPC win against MSD
23 March 2017   The English High Court has ruled that a supplementary protection certificate owned by Merck Sharp & Dohme is invalid because it didn’t comply with European regulations.
Americas
Teva and Amneal lose patent battle against Mallinckrodt
10 October 2016   Ireland-based biopharmaceutical company Mallinckrodt and Endo, a US healthcare business, have won a patent case against Amneal and Teva.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

More on this story

Big Pharma
Teva and generics in SPC win against MSD
23 March 2017   The English High Court has ruled that a supplementary protection certificate owned by Merck Sharp & Dohme is invalid because it didn’t comply with European regulations.
Americas
Teva and Amneal lose patent battle against Mallinckrodt
10 October 2016   Ireland-based biopharmaceutical company Mallinckrodt and Endo, a US healthcare business, have won a patent case against Amneal and Teva.

More on this story

Big Pharma
Teva and generics in SPC win against MSD
23 March 2017   The English High Court has ruled that a supplementary protection certificate owned by Merck Sharp & Dohme is invalid because it didn’t comply with European regulations.
Americas
Teva and Amneal lose patent battle against Mallinckrodt
10 October 2016   Ireland-based biopharmaceutical company Mallinckrodt and Endo, a US healthcare business, have won a patent case against Amneal and Teva.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility